Mild Haemostatic Problems Associated with Congenital Heterozygous α2-Antiplasmin Deficiency

F W G Leebeek; J Stibbe; E A R Knot; C Kluft; M J Gomes; M Beudeker

doi:10.1055/s-0038-1646773

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1988; 59(01): 096-100
DOI: 10.1055/s-0038-1646773

Review Article

Schattauer GmbH Stuttgart

Mild Haemostatic Problems Associated with Congenital Heterozygous α₂-Antiplasmin Deficiency

F W G Leebeek

^*The Department of Haematology of the University Hospital Dijkzigt, Rotterdam, The Netherlands

,

J Stibbe

^*The Department of Haematology of the University Hospital Dijkzigt, Rotterdam, The Netherlands

,

E A R Knot

^**The Department of Internal Medicine II of the University Hospital Dijkzigt, Rotterdam, The Netherlands

,

C Kluft

^***Gaubius Institute TNO, Leiden, The Netherlands.

,

M J Gomes

^*The Department of Haematology of the University Hospital Dijkzigt, Rotterdam, The Netherlands

,

M Beudeker

^*The Department of Haematology of the University Hospital Dijkzigt, Rotterdam, The Netherlands

› Author Affiliations

Abstract

PDF Download

Summary

A Dutch family, of which 13 members are heterozygotes, deficient for α₂-antiplasmin (α₂-AP) is reported. Clinical studies showed that 2 heterozygotes had a mild bleeding tendency, which presented as bleeding episodes after tooth extraction and after surgery and, in one patient, also as excessive menstruation. Laboratory investigations revealed an α₂-AP activity of 62% (51-71) (median and range) and an antigen level of 60% (60-66). The plasminogen binding as well as the fibrin binding properties of α₂-AP were normal. Plasminogen concentrations were significantly higher in the heterozygotes compared to the other family members. However, free plasminogen not bound to histidine-rich glycoprotein was not significantly different between these two groups. We propose that in this family the deficiency of α₂-AP is due to a decreased synthesis of a normal α₂-AP molecule. This present study brings the frequency of heterozygous α₂-AP deficient patients with a bleeding tendency to 13 out of 59 heterozygotes reported in the literature.

Key words

Fibrinolysis - α₂-antiplasmin - Deficiency - Plasminogen - Haemorrhagic diathesis

PDF (568 kb)

References

References
1 Collen D. Identification and some properties of a new fast reacting plasma inhibitor in human plasma. Eur J Biochem 1976; 69: 209-216
2 Moroi M, Aoki N. Isolation and characterization of α₂-plasmin inhibitor from human plasma. J Biol Chem 1976; 251: 5956-5965
3 Saito H, Goodnough LT, Knowles BB, Aden DP. Synthesis and secretion of ob-plasmin inhibitor by established human liver cell lines. Proc Natl Acad Sci 1982; 79: 5684-5687
4 Hogstrop H, Saldeen T. Synthesis of α₂-antiplasmin by rat liver cells. Thromb Res 1982; 28: 19-25
5 Miillertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J 1976; 159: 545-553
6 Wiman B, Collen D. Purification and characterization of human antiplasmin, the fast acting plasmin inhibitor in plasma. Eur J Biochem 1977; 78: 19-26
7 Collen D, Wiman B. Fast-acting plasma inhibitor in human plasma. Blood 1978; 51: 563-569
8 Clemmensen I. Different molecular forms of α₂-antiplasmin. In: The physiological inhibitors of coagulation and fibrinolysis Collen D, Wiman B, Verstraete M. eds. Elsevier North Holland, Paramedical Press; Amsterdam: 1979: 131-136
9 Wiman B. Affinity-chromatographic purification of human α₂-antiplasmin. Biochem J 1980; 191: 229-232
10 Mimuro J, Kimura S, Aoki N. Release of α₂-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. It’s effect on fibrinolysis. J Clin Invest 1986; 77: 1006-1013
11 Moroi M, Aoki N. Inhibition of plasminogen binding to fibrin by α₂-plasmin inhibitor. Thromb Res 1977; 10: 851-856
12 Sakata Y, Aoki N. Cross-linking of α₂-plasmin inhibitor to fibrin stabilizing factor. J Clin Invest 1980; 65: 290-297
13 Kluft C, Los P. Demonstration of two forms of α₂-antiplasmin in plasma by modified crossed immunoelectrophoresis. Thromb Res 1981; 21: 65-71
14 Kluft C, Los P, Jie AF H, van Hinsbergh VW M, Vellenga EM, Jespersen JM, Henny Ch PM. The mutual relation of the two molecular forms of the major fibrinolysis inhibitor, α₂-antiplasmin in blood. Blood 1986; 67: 616-622
15 Clemmensen I, Thorsen S, Miillertz S, Petersen LC. Properties of three different molecular forms of the α₂-plasmin inhibitor. Eur J Biochem 1981; 120: 105-112
16 Kluft C, Los P, Jie AF H. The molecular form of α₂-antiplasmin with affinity for plasminogen is selectively bound to fibrin by factor XIII. Thromb Res 1984; 33: 419-425
17 Koie K, Kamiya T, Ogata K, Takamatsu J, Kobakura M. α₂-plasmin inhibitor deficiency (Miyasato disease). Lancet 1978; II: 1334-1336
18 Aoki N, Saito H, Kamiya T, Koie K, Sakata Y, Kobakura M. Congenital deficiency of α₂-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest 1979; 63: 877-884
19 Kluft C, Vellenga E, Rrommer EJ P. Homozygous α₂-antiplasmin deficiency. Lancet 1979; II: 206
20 Kluft C, Vellenga E, Brommer EJ P, Wijngaards G. A familial hemorrhagic diathesis in a Dutch family: An inherited deficiency of α₂-antiplasmin. Blood 1982; 59: 1169-1180
21 Miles LA, Plow EF, Donnelly KJ, Hougie C, Griffin JH. A bleeding disorder due to deficiency of α₂-antiplasmin. Blood 1982; 59: 1246-1257
22 Yoshioka A, Kamitsuji H, Takase T, Lida Y, Tsukada S, Mikami S, Fukui H. Congenital deficiency of α₂-plasmin inhibitor in three sisters. Haemostasis 1982; 11: 176-184
23 Stormorken H, Gogstad GO, Brosstad F. Hereditary α₂-antiplasmin deficiency. Thromb Res 1983; 31: 647-651
24 Kettle P, Mayne RR. A bleeding disorder due to a deficiency of α₂-antiplasmin. J Clin Pathol 1985; 38: 428-429
25 Kordich L, Feldman L, Porteie P, Lago O. Severe hemorrhagic tendency in heterozygous α₂-antiplasmin deficiency. Thromb Res 1985; 40: 645-651
26 Knot EA R, Ten Cate JW, Lamping RJ, Gie LiemKian. α₂-antiplasmin: Functional characterization and metabolism in a heterozygote deficient patient. Thromb Haemostas 1986; 55: 375-378
27 Abildgaard U, Lie M, Odegard OR. Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and Chromozym TH). Thromb Res 1977; 11: 549-553
28 Friberger P, Knos M, Gustavsson S, Aurell L, Cleason G. Methods for the determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 1978; 7: 138-145
29 Laurell CB. Quantitative estimations of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 57-65
30 Kluft C, Preston FE, Malia RG, Bertina RM, Wijngaards G, Greaves M, Verheijen JH, Dooijewaard G. Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults. Thromb Haemostas 1984; 51: 157-164
31 Koopman J, Haverkate F, Koppert P, Nieuwenhuizen W, Brommer EJ P, van der Werf WG C. A new enzyme immunoassay of fibrin(ogen) degradation products in plasma using a monoclonal antibody. In: Fibrinogen-Fibrin Formation and Fibrinolysis Vol.4 Lane DA, Henschen A, Jasani MK. eds. De Gruyter&Co; Berlin: 1986: 261-270
32 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basel) 1957; 17: 237-246
33 Recent Developments on Protein C. Boehringer Mannheim GmbH. Catno 4308 October 1983
34 Verheijen JH, Mullaart E, Chang GT G, Kluft C, Wijngaards G. A simple sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measuiement in plasma. Thromb Haemostas 1982; 48: 266-269
35 Verheijen JH, Chang GT G, Kluft C. Evidence for the occurrence of a fast acting inhibitor of tissue type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
36 Kluft C, Brakman P, Veldhuyzen-Stolk EC. Screening of fibrinolytic activity in plasma euglobulin fractions on the fibrin plate. In: Progress in chemical fibrinolysis and thrombolysis Davidson JF, Samama MM, Desnoyers PC. eds. Vol.2 57-65 Raven Press; New York: 1976
37 Chohan IS, Vermylen J, Singh I, Balakrishnan K, Verstraete M. Sodium acetate buffer: A diluent of choice in the clot lysis time technique. Thrombos Diathes Haemorrh 1975; 33: 226-229
38 Nieuwenhuis HK, Kluft C, Wijngaards Gv, Berkel W, Sixma JJ. α₂-Antiplasmin Enschede: An autosomal recessive hemorrhagic disorder caused by a dysfunctional α₂-antiplasmin molecule. Thromb Haemostas 1983; 50: 170 (Abstr)
39 Kluft C, Nieuwenhuis HK, Rijken DC, Groeneveld E, Wijngaards Gv, Berkel W, Dooijewaard G, Sixma JJ. α₂-Antiplasmin Enschede: A dysfunctional α₂-antiplasmin molecule, associated with an autosomal recessive hemorrhagic disorder. J Clin Invest 1987 (in press)